CHA Biotech said on the 15th it secured a 10 billion won equity investment from LG CNS, a company specializing in AI transformation (AX). The two companies also signed an agreement to cooperate on AX and digital transformation (DX) businesses.
In this partnership, LG CNS will take part in a paid-in capital increase through a new share allocation worth 10 billion won conducted by CHA Biotech, the holding company of CHA Bio Group. The cooperation will be pursued through Digital Healthcare affiliates, including CHA Biotech, CHA Healthcare, CHA AI Healthcare and Kakao Healthcare, with CHA Biotech at the center.
In the short term, the companies will push to build a smart big data platform that integrates data dispersed across hospitals, research institutes, pharmaceuticals and medical services, alongside a cloud infrastructure transition across CHA Bio Group. They also plan to apply AI-based systems to therapeutic manufacturing facilities to improve process efficiency.
In the mid to long term, they will jointly commercialize an "AI-based connected healthcare service." AI will analyze health and lifestyle data collected from hospitals, residential spaces and wearable devices, and when signs of abnormalities are detected, the service will automatically link to medical staff, provide care guidance and trigger emergency response. To that end, they will also review the feasibility of building a big data platform specialized for healthcare that integrates and refines medical, genomic and lifestyle data using LG CNS's small language model (sLLM) and EXAONE (LG AI Research).
The two companies will also cooperate to strengthen their digital foundation for global expansion. They will push to apply the connected healthcare service overseas by using CHA Bio Group's hospital networks in the United States, Singapore, Australia and Japan. Based on accumulated data and operational experience, they also plan to seek expansion into related industries such as finance.
Cha Won-tae, vice chair of CHA Bio Group and CSO of CHA Biotech, said, "AX and DX are key elements for securing competitiveness and future growth," adding, "We will deliver tangible results through cooperation with LG CNS."
Cha Won-tae, vice chair of CHA Bio Group and chief strategy officer (CSO) of CHA Biotech, said, "Amid a rapidly changing industrial environment, AX and DX are essential elements for securing competitiveness and future growth," adding, "We will create meaningful success stories through cooperation with LG CNS, which has core capabilities in the IT business field."